Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Breezula (cb-03-01) and kx-826 are discussed as hair loss treatments. Kx-826 is available on Kintor's website, while Breezula is available on the grey market.

PP405 is expected to be on the market between 2027 and 2030, with phase 3 trials starting in 2026. There is skepticism about its fast-tracking due to its cosmetic nature, and it may appear on the gray market sooner.

A user shared their 4-year progress using 1mg daily finasteride for hair loss, noting significant improvement without side effects. They did not use minoxidil tablets due to availability issues but are satisfied with their results.

PP405 is suspected to be a scam, with users doubting its legitimacy and effectiveness. Many recommend using proven treatments like finasteride and minoxidil.

PP405 shows promising results for hair density improvement, potentially outperforming Minoxidil in a shorter time. However, its public release is expected around 2029/2030, and its cost and availability remain uncertain.

A user in the UAE is facing customs issues with ordering Fluridil (Eucapil) and is considering ordering smaller quantities or switching to Pyrilutamide. They are also using finasteride daily to maintain hair and are unsure of Fluridil's effectiveness.

A 47-year-old male started using Minoxidil, Finasteride, Nizoral, Dermapen, and vitamins after his hair transplant was postponed due to COVID-19. He reported positive progress in hair growth over eight weeks with this routine.

PP405 is considered a promising hair loss treatment, potentially replacing minoxidil but not finasteride. Users are hopeful for future treatments like GT20029 and VDPHL01, while remaining cautious about effectiveness and side effects.

The user experienced significant hair regrowth using KX-826 (pyrilutamide) 0.9% over one year, despite initial shedding phases. They reported no side effects and have stabilized hair loss with consistent use.

The user shared a 14-month progress update using a 4-in-1 topical solution containing 0.3% finasteride, 7% minoxidil, 2.2% ketoconazole, and 0.2% biotin, applied nightly. They reported good results without microneedling and prefer the topical form over oral medication.

PP405 shows promise in treating severe hair loss, with 31% of users experiencing over 20% hair density increase in four weeks, faster than minoxidil and finasteride. Some users are skeptical about the results' significance and long-term efficacy.

The conversation discusses using topical dutasteride with a dermapen for hair loss treatment. The user is deciding between liposomal and mesosomal formulations for this purpose.

Clascoterone 5% topical solution is effective and safe for long-term use in treating male pattern hair loss. Cosmo Pharma aims for EU and US approval, with a potential US release in late 2027 or early 2028.

The conversation is about using micro needling and PTD-DBM for hair loss treatment. The user applies PTD-DBM drops on weekdays and performs micro needling weekly.

The user is seeking an alternative solvent for pyrilutamide due to skin irritation from ethanol and propylene glycol. They experienced similar issues with topical minoxidil.

Pelage Pharmaceuticals is starting Phase 3 trials for PP405 in September 2026, with potential market release by 2030. Users discuss various hair loss treatments like minoxidil, finasteride, RU58841, kx, breezula, and gt20029, expressing hope for future hair restoration.

A 33-year-old male shared his 4-month hair growth progress using 1mg finasteride and 2.5mg minoxidil daily, along with hair supplements and a serum containing Redensyl, Anagain, Capixyl, and Procapil. He reported thickening of existing hair and new hair growth without side effects.

A user shared their positive experience with a 4-in-1 topical solution containing finasteride, minoxidil, ketoconazole, and biotin, along with weekly microneedling using a 1.2mm dermastamp. The user reported no noticeable side effects and mentioned that the biotin likely doesn't contribute to hair growth.

A 23-year-old shared their positive 4-month progress using 1mg oral finasteride and topical minoxidil for hair loss, noting increased hair health and confidence despite initial shedding. Other users shared similar experiences and results, with some using Kirkland Costco minoxidil.

A 57-year-old man with male pattern hair loss and insulin resistance experienced hair regrowth and weight loss after using tirzepatide, without other hair treatments. Dysregulated glucose metabolism is linked to hair loss, with tirzepatide potentially improving hair density by normalizing insulin resistance.

The user has been using a finasteride and minoxidil combo spray from Hims for four months, with positive results and no side effects. They apply four sprays nightly, targeting the crown and front of the scalp.

The conversation is about hair loss treatments, focusing on finasteride and considering a switch to dutasteride due to hairline recession. Users suggest trying minoxidil or dermarolling before switching, while others recommend dutasteride for more aggressive hair loss.

The conversation discusses using PGE2 as a hair growth stimulant, comparing it to minoxidil, and considering the addition of Setipiprant. Concerns about side effects like skin damage and cost are also mentioned.

PP405 is likely a scam, with concerns about its legitimacy and safety, as it may cause unintended tissue growth. Users suggest sticking to known treatments like finasteride and minoxidil.

PP405 might take 3-4 years to be available, but some claim Everychem offers a similar product, though its effectiveness is debated. Users discuss the risks of using untested grey market products and the potential for adverse effects.

A phase 3 trial for Breezula (clascoterone solution) to treat male pattern hair loss has been listed, with 726 participants and a completion date of January 2025. Other treatments mentioned include Aneira Pharma's combination of minoxidil and latanoprost, Triple Hair's combination of minoxidil, latanoprost, and finasteride, and a new microneedling and LLLT device called StimuSIL.

Spraying pyrilutamide on the crown area shows noticeable improvement compared to using a dropper. Applying directly to the vertex is challenging without wasting the product.

A user is attempting to reformulate a topical gel using PP-405 for hair loss, aiming to enhance its effectiveness with additional compounds. They discuss the potential of PP-405 compared to other treatments like Minoxidil and GT20029, and emphasize the importance of proper formulation for efficacy.

VDPHL01 is discussed as a potential replacement for DHT blockers, with comparisons to minoxidil. Users express skepticism about its effectiveness without addressing DHT, suggesting it may only slow hair loss rather than stop it.

A 36-year-old started using 0.5mg finasteride and 2.5mg oral minoxidil daily for hair loss, reporting positive results without side effects. Despite criticism about photo lighting, the user remains optimistic about continued improvement.